GENERAL29 Sept 2026
SC flags a costly dose of markups, asks for 16% cap on essential meds
The Supreme Court has asked the Centre why the maximum retail price (MRP) of essential medicines, including cancer drugs, cannot be capped at 16 per cent. A Bench of Justices Vikram Nath and Sandeep Mehta flagged the wide gap between the cost at which medicines reach retailers and what patients finally pay. The matter is still being heard, so no price change has been ordered yet.
Key Statutory Highlights
- A Supreme Court Bench of Justices Vikram Nath and Sandeep Mehta asked the Centre why the MRP of essential medicines such as cancer drugs could not be capped at 16 per cent.
- The Bench flagged the wide gap between the cost at which medicines reach retailers and the price ultimately paid by patients.
- The report was first published on September 29, 2026.
Actionable Advice for Taxpayers / Founders:If you deal in essential medicines, wait for an official order before changing any prices, since the Court has only asked the Centre a question and no cap has been ordered yet.
Statutory Disclaimer: TaxQue Shorts are AI-assisted editorial briefs for compliance awareness. This brief has not passed every source check; confirm the original notification before acting. This does not constitute formal legal or CA counsel.
TaxQue News Desk
Share: